Plasma biomarkers discrimination accuracy of biologically defined Alzheimer’s disease in a memory clinic setting

Documenti analoghi

• A head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
  di: Federica Anastasi, et al.
  Pubblicazione: (2025)
• Sensitive methods to define subtle memory decline capture intra‐individual hippocampal atrophy and increased cortical volumes in preclinical Alzheimer’s
  di: David López‐Martos, et al.
  Pubblicazione: (2024)
• Diagnostic blind spot in clinical manifestations: anosognosia trajectory in preclinical Alzheimer's is linked to core pathophysiology, astrocytic reactivity, and structural changes in cognitive control and self‐referential brain regions
  di: David López‐Martos, et al.
  Pubblicazione: (2025)
• Voxel‐wise longitudinal changes between amyloid PET and executive function subcomponents at the preclinical stage of the Alzheimer's continuum
  di: David López‐Martos, et al.
  Pubblicazione: (2025)
• Plasma biomarkers combinations for prescreening rapid amyloid accumulation in cognitively unimpaired individuals at‐risk of Alzheimer’s disease
  di: José Contador, et al.
  Pubblicazione: (2024)